Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute
Download Here

To increase awareness and management of adverse effects related to trifluridine/tipiracil treatment in metastatic colorectal cancer.

Continue reading Trifluridine / Tipiracil for Treatment of Gastric Cancer

Read More

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers
Download Here

The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib. Continue reading Duvelisib for Chronic Lymphocytic Leukemia and Follicular Lymphoma

Read More

Written by: Eric Dallara, RPh, New England Cancer Specialist
Download Here

Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the Neratinib arm in which antidiarrheal prophylaxis was not protocol specified.1  Various prevention and treatment strategies for diarrhea have been studied and will be discussed in this PQI. Continue reading Neratinib Diarrhea Management

Read More

Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology
Download Here

Treatment options for patients with carcinoid syndrome diarrhea that is refractory to somatostatin analog (SSA) therapy are limited. A first in class oral tryptophan hydroxylase inhibitor, telotristat ethyl, was approved in February for 2017 for use in combination with SSA therapy in adults with carcinoid syndrome diarrhea inadequately treated with SSA. Continue reading Telotristat ethyl: Carcinoid Syndrome Diarrhea

Read More

Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health
Download Here

Cyclin-dependent kinase (CDK) 4/6 inhibitors have demonstrated significant advances in the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor (HER2) negative advanced breast cancer. While current available data do not support the preferential use of one agent over the other, the dosing and safety monitoring differ and may help in treatment decision making with patients. Multi-disciplinary care teams have key roles in education and supportive care management to optimize the use of these agents and disease response1,2. Continue reading CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

Read More